Lung Cancer, Lung Tuberculosis
Conditions
Keywords
68Ga, Alfatide II, RGD, αvβ3, PET/CT
Brief summary
Comparison of 68Ga-AlfatideII and 18F-FDG in differential diagnosis effectiveness towards the solitary pulmonary nodules of lung cancer or tuberculosis.
Interventions
Sponsors
Study design
Eligibility
Inclusion criteria
* Must be able to provide a written informed consent * Males and females, ≥18 years old. * The definite diagnosis of lung cancer was established by pre-operational bronchoscopic or puncture biopsy or the definite diagnosis of lung tuberculomas was established on the basis of positive sputum culture examinations and confirmed by follow-up. * Without any treatment or resection surgury. * All the biopsies are done at least 10 days before PET/CT scans. * Evaluation of cardiac function.
Exclusion criteria
* Females planning to bear a child recently or with childbearing potential; * Known severe allergy or hypersensitivity to IV radiographic contrast; * Inability to lie still for the entire imaging time because of cough, pain, etc. * Inability to complete the needed examinations due to severe claustrophobia, radiation phobia, etc. * Concurrent severe and/or uncontrolled and/or unstable other medical disease that, in the opinion of the investigator, may significantly interfere with study compliance.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Quantitative measurement of standardized uptake values (SUVs) of lesions. | 1 year | The quantitative analysis will be performed by the same person for all cases, and the standardized uptake value (SUV) of each tumor will be measured using a volume of interest (VOI) method. |
Secondary
| Measure | Time frame |
|---|---|
| Number of participants with adverse events as a measure of safety after 68Ga-NEB injection and PET/CT scanning. | 1 year |